Why this Matters
If you have high blood pressure, high cholesterol, diabetes or pre-diabetes, osteoporosis (bone loss), or reproductive issues, and you have a benign tumor on your adrenal gland or pituitary gland, it is possible that these conditions are caused by elevated hormone levels produced by that tumor.
Sparrow Pharmaceuticals is conducting clinical trials of an investigational drug that may help patients who have excessive cortisol as a result of their tumor or Cushing’s disease.
Sparrow Pharmaceuticals currently has two ongoing studies for people with various forms of hypercortisolism. To learn more about the studies or find out if you may be eligible, click on the study-specific link:
Autonomous cortisol secretion (ACS) and adrenal Cushing’s syndrome (aCs)
Adrenocorticotropic hormone-dependent Cushing’s Syndrome (ACTH Cushing’s)
About the Study Drug
The investigational drug being tested in these studies is an oral tablet called SPI-62. It may reduce the conversion of cortisone into cortisol in the body’s tissues. The ACSpire and RESCUE studies will help to better understand the drug’s safety and efficacy as a potential treatment for hypercortisolism, as well as any other effects it might have.
The ACSpire study is for people with hypercortisolism (higher than normal levels of the adrenal “stress” hormone known as cortisol) related to a benign adrenal tumor. This is also known as autonomous cortisol secretion (ACS) or adrenal Cushing’s syndrome (aCs).
Participation will continue in an open-ended fashion until SPI-62 either becomes commercially available or is terminated.
The RESCUE study is for people with Cushing’s syndrome caused by a non-adrenal tumor (tumor in the pituitary gland or some other location). This is also called ACTH-dependent Cushing’s disease or syndrome (ACTH stands for adrenocorticotropic hormone).
Participation lasts 7 months and requires at least 11 visits to the research site. Four of these visits may be done remotely at your home.